Synopsys (SNPS) Could Be 22% Undervalued Following Fresh Analyst Optimism

Simply Wall St

Synopsys (SNPS) has been drawing fresh attention after being dropped from several Russell growth and defensive indexes, even as analyst earnings estimate revisions and search interest highlight renewed focus on the stock.

See our latest analysis for Synopsys.

At a latest share price of US$437.16, Synopsys has seen its 1 day share price return fall 3.82% and its 30 day share price return decline 5.96%. However, the 90 day share price return is up 10.10% and the 5 year total shareholder return is 55.71%, suggesting long term holders have still seen gains despite more recent pressure and index removals.

If Synopsys has you thinking about the wider AI opportunity, this is a good moment to widen your search with 62 profitable AI stocks that aren't just burning cash

With Synopsys trading below analyst price targets and recent returns under pressure, investors are asking a simple question: is the stock offering genuine value today, or is the market already pricing in much of its future growth?

Most Popular Narrative: 21.9% Undervalued

Compared with Synopsys' last close at $437.16, the most widely followed narrative points to a higher fair value and frames that gap using detailed earnings and revenue projections under a specific discount rate of 8.91%.

The acquisition and integration of Ansys positions Synopsys as the global leader in engineering solutions from silicon to systems, dramatically expanding its addressable market into sectors like automotive, industrial, and aerospace. This is expected to support long-term top-line growth as more sophisticated and complex products, especially AI-powered and smart devices, require robust simulation, analysis, and EDA tools.

Read the complete narrative.

Want to see what sits behind that fair value gap? The narrative focuses on faster earnings growth, higher margins, and a richer profit multiple than many investors might assume at first glance.

Result: Fair Value of $559.58 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Synopsys still faces meaningful risks, including prolonged export restrictions affecting China revenue and the possibility that Ansys integration or IP transitions prove more costly than expected.

Find out about the key risks to this Synopsys narrative.

Another View: Multiples Paint A Tougher Picture For Synopsys

While the SWS model points to Synopsys trading about 11.7% below its estimated fair value, the earnings multiple tells a different story. The stock sits on a P/E of 108.3x, versus a fair ratio of 49x, the US Software industry at 27.7x, and peers around 33.3x. That gap suggests you are paying a rich premium, so it is worth considering how comfortable you are with that trade off.

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGS:SNPS P/E Ratio as at Jul 2026

Next Steps

If this combination of pressure and optimism around Synopsys leaves you undecided, move quickly, review the full data, and consider 3 key rewards and 3 important warning signs

Looking for more investment ideas beyond Synopsys?

If Synopsys has sharpened your focus on where to put fresh capital to work, do not stop here. Broaden your watchlist with other targeted opportunities.

  • Spot potential value plays early and compare them against Synopsys by scanning 44 high quality undervalued stocks that pair quality fundamentals with appealing pricing.
  • Strengthen your income stream and see how it sits alongside a growth stock like Synopsys by reviewing 7 dividend fortresses delivering substantial yields with staying power.
  • Protect your portfolio’s downside while you review higher growth ideas such as Synopsys by using 74 resilient stocks with low risk scores designed to highlight companies with more resilient profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Synopsys might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com